Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
Anti-angiogenesis Therapeutics in Cancer, Ocular and Skin Disorders
share announcement

Anti-angiogenesis Therapeutics in Cancer, Ocular and Skin Disorders

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cell Biology and Pathology".

Deadline for manuscript submissions: closed (15 February 2022) | Viewed by 8329

Special Issue Editor

Prof. Dr. Shaker A. Mousa

E-Mail Website
Guest Editor
1. Retired, The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, 1 Discovery Drive (Room 238), Rensselaer, NY 12144, USA
2. Vascular Vision Pharmaceuticals Co., Rensselaer Polytechnic Park, Troy, NY 12180, USA
Interests: pharmaceuticals; biopharmaceuticals and diagnostics; nanomedicine; cardiovascular diseases; neurological disorders; hematology and oncology; biosimilar and nanosimilar; angiogenesis; inflammation; thrombosis; integrin and cell adhesion molecules; target identification; molecular mechanisms and signaling pathways; preclinical; clinical; marketing and post marketing studies; regulatory and ethical issues
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The aim of this Special Issue is to cover the current status and future directions in the discovery and development of novel anti-angiogenesis strategies in oncology, eye diseases such as diabetic retinopathy (DR), and age-related macular degeneration (AMD), as well as dermatological disorders such as rosacea, poikiloderma, and psoriasis. The Special Issue aims to cover preclinical and clinical steps involved in the discovery and development of anti-angiogenesis targets in cancer and to discuss mechanisms involved in the modulation of angiogenesis in relation to cancer therapy. FDA-approved anti-angiogenesis agents will be reviewed. Furthermore, the implications of nanotechnology in expanding the utility of existing and novel anti-angiogenesis strategies in various pathological angiogenesis-associated disorders will also be reviewed.

Prof. Dr. Shaker Mousa
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Angiogenesis and anti-angiogenesis in hematological malignancies
  • angiogenesis and lymphogenesis in cancer (tumor growth, invasion, and metastasis)
  • survey of different anti-angiogenesis strategies
  • angiogenesis and anti-angiogenesis in eye diseases
  • angiogenesis and anti-angiogenesis in nonmalignant skin disorders
  • integrin in angiogenesis and lymphogenesis
  • anti-VEGF (vascular endothelial growth factor) in angiogenesis modulation and cancer therapy
  • tyrosine kinase inhibitors (TKI) in angiogenesis modulation and cancer therapy
  • multitargeted anti-angiogenesis therapy in cancer therapy
  • micro-RNA and angiogenesis modulation
  • naturally occurring anti-angiogenesis agents
  • angiogenesis biomarkers and impact on personalized management
  • combination of anti-angiogenesis and chemotherapeutics
  • nanotechnology in enhancing the utility of anti-angiogenesis agents—combinations with standard anti-cancer
  • nano-targeted anti-angiogenesis agents in cancer detection
  • diabetic retinopathy (DR)
  • age-related macular degeneration (AMD)
  • dermatological disorders, rosacea, poikiloderma, and psoriasis

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 3510 KiB  
Article
CD63+ and MHC Class I+ Subsets of Extracellular Vesicles Produced by Wild-Type and CD47-Deficient Jurkat T Cells Have Divergent Functional Effects on Endothelial Cell Gene Expression
by Sukhbir Kaur, Abdel G. Elkahloun, Jennifer D. Petersen, Anush Arakelyan, Ferenc Livak, Satya P. Singh, Leonid Margolis, Joshua Zimmerberg and David D. Roberts
Biomedicines 2021, 9(11), 1705; https://0-doi-org.brum.beds.ac.uk/10.3390/biomedicines9111705 - 17 Nov 2021
Cited by 2 | Viewed by 2243
Abstract
T cells and endothelial cells engage in bidirectional communication that regulates angiogenesis and T cell transmigration. Extracellular vesicles (EVs) mediate intercellular communication by the transfer of bioactive molecules including RNAs. EVs produced by a given cell type are heterogeneous in their RNA content, [...] Read more.
T cells and endothelial cells engage in bidirectional communication that regulates angiogenesis and T cell transmigration. Extracellular vesicles (EVs) mediate intercellular communication by the transfer of bioactive molecules including RNAs. EVs produced by a given cell type are heterogeneous in their RNA content, but it is unclear how specific EV surface markers relate to their functional effects on target cells. Our previous work established that Jurkat T cell EVs bearing CD63, MHC-I, or CD47 surface markers contain distinct noncoding RNA populations. The present study reveals that CD63+ and MHC-I+ EVs from CD47-deficient Jurkat T cells are enriched in small non-coding RNAs relative to EVs from wild-type Jurkat T cells. CD47-deficient Jurkat T cells secrete more CD63+ and MHC-I+ EVs, but MHC-I+ EVs are selectively taken up more by human umbilical vein endothelial cells. Transcriptomics analysis of endothelial cells treated with CD63+ or MHC-I+ EVs showed surface marker- and CD47-dependent changes in gene expression in the target cells. Gene set enrichment analysis identified CD47-dependent, and surface marker-dependent effects of T cell EVs on VEGF and inflammatory signaling, cell cycle, and lipid and cholesterol metabolism. Thus, subsets of T cell EVs differentially regulate endothelial cell metabolism and inflammatory and angiogenic responses. Full article
(This article belongs to the Special Issue Anti-angiogenesis Therapeutics in Cancer, Ocular and Skin Disorders)
►▼ Show Figures

Figure 1

21 pages, 3689 KiB  
Article
Profiles of Cytokines Secreted by ARPE-19 Cells Exposed to Light and Incubated with Anti-VEGF Antibody
by Tomohito Sato, Masaru Takeuchi, Yoko Karasawa and Masataka Ito
Biomedicines 2021, 9(10), 1333; https://0-doi-org.brum.beds.ac.uk/10.3390/biomedicines9101333 - 27 Sep 2021
Cited by 5 | Viewed by 1941
Abstract
The retinal pigment epithelium (RPE) is the major source of cytokines in the retina regulating the intraocular immune environment, and a primary target of photodamage. Here, we examined 27 types of cytokines secreted by ARPE-19 cells exposed to visible light and incubated with [...] Read more.
The retinal pigment epithelium (RPE) is the major source of cytokines in the retina regulating the intraocular immune environment, and a primary target of photodamage. Here, we examined 27 types of cytokines secreted by ARPE-19 cells exposed to visible light and incubated with aflibercept or ranibizumab, which are two anti-vascular endothelial growth factor (VEGF) antibodies. The cells were cultured for 24 h in the dark or under 2000 lux irradiation from a daylight-colored fluorescent lamp, and cytokine levels in the culture supernatant were measured. In the light-irradiated culture, the levels of IL-9, IL-17A and bFGF were higher, and the levels of IL-6, IL-7, IL-8 and MCP-1 were lower than those in the dark culture, while there was no significant difference with the VEGF-A level. In subgroup analyses of the light-irradiated culture, the bFGF level under 250 to 2000 lux irradiation was elevated in a light intensity-dependent manner. In culture exposed to blue, green or red light, the bFGF level was elevated by blue light and was high compared to that by green or red light. In culture with aflibercept or ranibizumab in the dark, the levels of IL-6, IL-8, bFGF and MCP-1 were increased, and the IL-12 level decreased synchronously with a reduction in the VEGF-A level. Our findings indicate that continuous irradiation of visible light and VEGF suppression may be an influential factor in expression patterns of inflammatory cytokines secreted by human RPE cells. Full article
(This article belongs to the Special Issue Anti-angiogenesis Therapeutics in Cancer, Ocular and Skin Disorders)
►▼ Show Figures

Figure 1

10 pages, 1678 KiB  
Article
Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy
by Yoshiko Fukuda, Yoichi Sakurada, Mio Matsubara, Yuka Hasebe, Atsushi Sugiyama, Wataru Kikushima and Kenji Kashiwagi
Biomedicines 2021, 9(9), 1164; https://0-doi-org.brum.beds.ac.uk/10.3390/biomedicines9091164 - 05 Sep 2021
Cited by 30 | Viewed by 3168
Abstract
We compared the short-term outcomes between 3-monthly aflibercept and brolucizumab injections for treatment-naïve polypoidal choroidal vasculopathy (PCV). A total of 52 eyes were included. Patients received 3 monthly intravitreal aflibercept (n = 38) or intravitreal brolucizumab (n = 14). Indocyanine green [...] Read more.
We compared the short-term outcomes between 3-monthly aflibercept and brolucizumab injections for treatment-naïve polypoidal choroidal vasculopathy (PCV). A total of 52 eyes were included. Patients received 3 monthly intravitreal aflibercept (n = 38) or intravitreal brolucizumab (n = 14). Indocyanine green angiography (ICGA) was performed at baseline and at the 3-month visit. Selection of anti-VEGF agents depended on time. In the brolucizumab-treated group, best-corrected visual acuity (BCVA) improved from 0.27 ± 0.34 (log MAR unit) at baseline to 0.20 ± 0.24 at 3-month visit, which is comparable with the aflibercept-treated group (p = 0.87), after adjustment of confounding factors. Central retinal thickness significantly decreased by 43%−44% in both groups. Subfoveal choroidal thickness also significantly decreased by 20.5% during this interval in the brolucizumab-treated group, which was greater than the aflibercept-treated group. The complete resolution rate of polypoidal lesions on ICGA was significantly higher (p = 0.043) in the brolucizumab-treated group (78.6%) than in the aflibercept-treated group (42.1%). Intraocular inflammation was observed in 14.3% (2/14) in the brolucizumab-treated group only. In short-term follow-up, intravitreal injection of 3-monthly brolucizumab was comparable with aflibercept in terms of BCVA and morphological improvement along with higher resolution of polypoidal lesion(s) on ICGA. Full article
(This article belongs to the Special Issue Anti-angiogenesis Therapeutics in Cancer, Ocular and Skin Disorders)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop